RE: SkinBio Q&A12 Dec 2025 11:28
Plenty not to like in Ashman's answers – although the patrons seemed to lap it up and he has at least been flushed out of his hiding place.
Bluff, bluster and deflection, with no blame attached to him…a cover-up. Whatever he says, the regulator investigations are ongoing so he doesn't know the outcome yet. He admitted that the 25% revenue miss was due to delayed orders in May and June - long before the 16 June fundraise by when the £5.3m + Croda forecast was certain to be missed by a material amount and should have been disclosed to the market. Ashman waited until 14 August to downgrade the forecast and the regulator – not Ashman or his lawyers – will decide whether that amounted to a misdemeanour.
Forecasts are an inexact science, especially without prior years' data, but a 25% miss enters the realm of incompetence, not least because Ashman did have prior data for all parts of the group including the two acquisitions and only lacked comparators for the Croda revenue - which was the one area which didn't disappoint since it hadn't been tainted by an Ashman forecast. Ashman has the nerve to describe this as "a slight miss". The 2026 forecast presumably now allows for a quiet Q4 for the acquisitions, following a bumper Q1.
FWIW, I still think that both new acquisitions were prudent purchases. The problem is that they were overhyped as immediately accretive, wrongly forecast and deceptively described as meeting expectations long after it must have been clear that they weren't.